Background: In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer. However, peripheral nerve disorders caused by OXA during mFOLFOX6 therapy can decrease patients' quality of life. OXA can be safely discontinued from a FOLFOX regimen after 6 cycles during first-line therapy. Also, for patients who discontinue OXA without having experienced peripheral nerve disorders, reintroducing OXA in the later stages of treatment could remain an option. Patients and Methods: The study is a phase II, multicenter, open-label, parallel-group, randomized, controlled exploratory study comparing the efficacy and safety of mFOLFOX6 plus panitumumab and 5-FU/LV plus panitumumab in patients with chemotherapy-naïve, unresectable, advanced or recurrent colorectal carcinoma of RAS wild-type (SAPPHIRE; ClinicalTrials.gov identifier, NCT02337946). Eligible patients will receive 6 cycles of mFOLFOX6 plus panitumumab combination therapy, followed by 1:1 randomization to either further treatment with mFOLFOX6 plus panitumumab or discontinuation of OXA and treatment with 5-FU/LV plus panitumumab. Up to 100 randomized patients will receive treatment for approximately 12 months or until any of the criteria for treatment discontinuation have been met. The primary endpoint is progression-free survival rate at 9 months after the day of randomization. The secondary endpoints are progression-free survival, overall survival, response rate, and interval to treatment failure. Safety will be evaluated according to the incidence and severity of adverse events, including the incidence of peripheral nerve and skin disorders. Additional endpoints will include maintenance of performance status, continuation of OXA in the mFOLFOX6 plus panitumumab group, and continuation of panitumumab in both groups.
Introduction
Worldwide, colorectal cancer is the third and second most commonly diagnosed cancer in men and women, respectively, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012. 1 In Japan, the incidence of colorectal cancer has been increasing each year, and, in 2016, colorectal cancer had the greatest projected incidence and was the second most common cause of cancer death. 2, 3 The treatment options that have shown clinical benefit in the first-line treatment of unresectable, advanced or recurrent colorectal cancer include an irinotecan/ 5-fluorouracil (5-FU)/leucovorin (LV) (FOLFIRI) or oxaliplatin (OXA)/5-FU/LV (FOLFOX6) backbone combined with either an anti-vascular endothelial growth factor antibody (bevacizumab) or an anti-epidermal growth factor receptor (EGFR) antibody (cetuximab or panitumumab). Another option is combination chemotherapy with OXA, irinotecan, 5-FU, and LV (FOLFOXIRI). 4 Japanese treatment guidelines recommend combination chemotherapy with molecular targeted drugs, such as bevacizumab or anti-EGFR antibody therapy; however, anti-EGFR antibody therapy should only be used in patients with RAS wild-type carcinoma. 5, 6 In Japan, modified FOLFOX6 (mFOLFOX6) combined with a molecularly targeted drug is the most frequently used first-line therapy for unresectable, advanced or recurrent colorectal carcinoma. 4 However, the OXA component of the mFOLFOX6
regimen can induce peripheral nerve disorders, which can make continuous treatment difficult. 7 In some cases, this can lead to discontinuation of treatment despite favorable responses, with some patients unable to receive effective, targeted treatment combinations. 8 However, OXA can be safely discontinued from a frontline FOLFOX regimen after 6 cycles without compromising overall efficacy, which was shown in the OPTIMOX1 study. 8 Furthermore, for patients who discontinue OXA without having experienced peripheral nerve disorders, reintroducing OXA in the later stages of treatment could remain an option. 9 At present, an optimal administration method for OXA in firstline therapy with mFOLFOX6 plus panitumumab has not yet been reported. Therefore, the present randomized phase II study is evaluating the effect of discontinuing OXA after 6 cycles of frontline treatment with mFOLFOX6 plus panitumumab versus the continuation of OXA therapy for patients without progressive disease after the first 6 cycles. According to previous studies, 10, 11 an average of 7 to 10 OXA doses are administered continuously in initial FOLFOX therapy; thus, discontinuation of OXA after the sixth administration in the present study is consistent with routine medical care. Moreover, because no significant differences were seen in the duration of disease control or progression-free survival (PFS) in the OPTIMOX1 study, 8 the duration of treatment is not expected to differ significantly even when OXA is discontinued after 6 cycles.
Discussion

Study Design and Treatment
This is a phase II, multicenter, open-label, parallel-group, randomized, controlled, exploratory study comparing the efficacy and safety of mFOLFOX6 plus panitumumab and 5-FU/LV plus panitumumab in patients with chemotherapy-naïve unresectable advanced or recurrent colorectal carcinoma of RAS wild-type after 6 cycles of combination therapy with mFOLFOX6 plus panitumumab (SAPPHIRE; ClinicalTrials.gov identifier, NCT02337946; Figure 1 ). All eligible patients will receive mFOLFOX6 plus panitumumab combination therapy, once every 2 weeks, for 6 cycles: OXA 85 mg/m 
Patients
Patients with RAS (KRAS and NRAS ) wild-type colorectal cancer are being identified using the MEBGEN RASKET kit (approved for use April 2015). Additional eligibility criteria for enrollment are shown in Supplemental Table 1 (available in the online version). After the initial 6 cycles of mFOLFOX6 plus panitumumab, the patients must also meet additional eligibility criteria for randomization to mFOLFOX6 plus panitumumab or 5-FU/LV plus panitumumab (Supplemental Table 1 ; available in the online version).
Throughout the study, patients will be able to receive adequate supportive care for neutropenia, nausea/vomiting, allergic reactions, and interstitial pneumonia. However, chemotherapy or antibody therapy (other than the protocol treatment), hormonal therapy, immunotherapy, vaccine therapy, cytokine therapy, biologic response modifiers, gene therapy, and radiotherapy are contraindicated.
Endpoints and Assessments
The primary endpoint is the PFS rate at 9 months after the day of randomization. The secondary endpoints are PFS, overall survival (OS), response rate, time to treatment failure (TTF), the incidence and severity of adverse events (AEs), the incidence of peripheral nerve disorders, and the incidence of skin disorders. Additional endpoints include maintenance of performance status, continuation of OXA in the mFOLFOX6 plus panitumumab group (group A), and the continuation of panitumumab in both groups.
PFS is defined as the period from randomization (day 0; ie, after the first 6 cycles of therapy with mFOLFOX6 plus panitumumab) until progression or death from any cause, whichever comes first. The PFS rate at 9 months is defined as the proportion of patients alive and without progressive disease 9 months after randomization. If patients undergo surgical resection before 9 months, they will be considered to be without progressive disease, unless a new lesion has developed. OS is defined as the period from the day of randomization (day 0) until death from any cause. TTF is defined as the period from the date of randomization (day 0) to the date of discontinuation, progression, or death by any cause, whichever comes first. The response will be assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.1. 12 The frequency, severity, and relatedness of AEs will be recorded, and the AEs will be graded according to the Common Terminology Criteria for Adverse Events, Japanese edition (JCOG version v4.03).
Target Sample Size and Statistical Analysis
The purpose of the present study is to assess the difference in PFS with mFOLFOX6 plus panitumumab versus 5-FU/LV plus panitumumab. Based on previous studies, 13, 14 the PFS rate at 9 months in group A is expected to be w50%, with a comparable PFS rate at 9 months in group B. In the primary analysis, a binomial test will be conducted separately for each group for the null hypothesis: "the true PFS rate at 9 months will be less than the threshold 30% PFS rate at 9 months and the treatment judged as ineffective." Using a threshold 30% PFS rate at 9 months, a true 50% PFS rate at 9 months, 1-sided significance level of 10%, and 90% power, 44 patients will be required in each group. Considering patient discontinuation, the target number of patients to be randomized was set at 50 patients for each group (100 patients total). The intention-to-treat population consists of all randomized patients, regardless of whether they were eligible or had received any study medication. All efficacy analyses will be performed on this population according to the allocated treatment, rather than to the treatment actually received. If the null hypothesis is rejected by the binomial test results in each group, the treatment regimen concerned will be regarded as worthy of further investigation. The PFS rate at 9 months is shown as the proportion of patients without progressive disease; its 80% 2-sided confidence interval (CI) was calculated using the Agresti-Coull method.
The time-to-event endpoints (PFS, OS, and TTF) will be calculated using the Kaplan-Meier method, with the corresponding median and quartile values (and 2-sided 95% CIs) for each treatment group. Because this study is a phase II randomized screening comparison study, it is using a direct comparison for the primary analysis. However, although the trial is noncomparative in nature, SAPPHIRE Study: Rationale and Design the risk difference between groups A and B will be calculated using the 95% CI based on the Agresti-Caffo method as a reference for future clinical study. The hazard ratio of group B to group A and its 95% CI (2-sided) will also be calculated. The hazard ratio adjusted for the allocation factor will also be calculated using the Cox regression model.
Conclusion
This is an exploratory randomized phase II study to explore the efficacy and safety of mFOLFOX6 plus panitumumab versus 5-FU/LV plus panitumumab in patients with chemotherapy-naïve unresectable, advanced or recurrent colorectal carcinoma of RAS wild-type after receipt of 6 cycles of first-line mFOLFOX6 plus panitumumab. The first patient was enrolled in the study in the Aizawa Hospital on October 20, 2014. Patients were enrolled across 72 sites in Japan, and enrollment was completed on April 26, 2016.
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